Wes Streeting calls John Swinney an 'analogue politician'
Plans to create an NHS Scotland app are under way but are currently limited to a trial for dermatology patients in NHS Lanarkshire. A national rollout is not expected before the end of the decade.
Streeting said there was 'no excuse' for the devolved government not have to have introduced an app similar to the one in England, which has been in place for six years.
READ MORE: From Lewis Capaldi to a long-awaited apology – plenty to be positive about in June
It follows his pledge to improve the use of technology in the NHS south of the border.
Last week, Streeting launched plans to give patients in England a 'doctor in your pocket' as he announced improvements to the country's NHS app, which already has 35 million users.
It currently allows patients to book appointments with their GP, order prescriptions and manage hospital appointments.
Streeting said the lack of an app in Scotland showed why Scotland 'can't afford a third decade of the SNP'.
The Health Secretary said: 'The UK Labour Government is embracing technology to deliver a better NHS for patients and their families, giving them more control and transparency over their treatment.
'In John Swinney, the SNP have an analogue politician in a digital age, and patients in Scotland are missing out.
'The SNP have record funding and complete control of the NHS in Scotland, there's no excuses for this, and it just shows why Scotland can't afford a third decade of the SNP and needs a new direction with Anas Sarwar as first minister.'
The Scottish Government has been approached for comment.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Powys County Times
29 minutes ago
- Powys County Times
Medicine shortages put patients at risk, MPs and peers warn
Patients are facing serious harm from persistent and widespread medicine shortages, MPs and peers have warned. A new report from the All-Party Parliamentary Group (APPG) on pharmacy called for urgent action to ensure shortages do not become the 'new normal'. It also highlights the impact that shortages are having on patients with the likes of ADHD (attention deficit hyperactivity disorder), menopause and diabetes. Writing in the report, Steve Race, chairman of the APPG on pharmacy, said many MPs 'have received a growing volume of correspondence from constituents who are understandably anxious about the availability of their medicines'. 'Whether it is a parent unable to access antibiotics for a sick child, an elderly patient facing delays in obtaining life-sustaining medication, or a pharmacist overwhelmed by the need to source alternatives, the human impact is both visible and deeply troubling,' he wrote. The report said that while medicine shortages are 'not a new phenomenon', they have 'become increasingly severe, persistent, and disruptive' in recent years – leading to consequences for patients, staff and the wider health service. Mr Race said: 'Medicines shortages have moved from isolated incidents to a chronic structural challenge for both the NHS and pharmacy sector. 'As Government continues to recognise and invest in the expanded clinical role of community pharmacy, we must ensure the medicines supply chain underpinning that care is equally robust, resilient and patient-focused. 'Pharmacy is central to NHS recovery and transformation, but frontline teams cannot safely expand clinical services while daily supply disruptions continue to impact the health of patients.' The findings also highlight how shortages severely impact patients with conditions like ADHD, menopause and diabetes. More than nine in 10 pharmacists, GPs and prescribers told an APPG survey ADHD medicines had been affected by shortages. Around three quarters (76%) said HRT and diabetes drugs had been affected, while 44% said antibiotics. One patient with ADHD told the inquiry they had been self-medicating with cannabis due to an ongoing shortage of methylphenidate. The report said: 'These shortages are having a significant impact on patients' ability to access treatments and in some cases are having serious impact on patients' health and well-being.' Mr Race added: 'Medicines security must be treated as a core component of NHS planning, alongside funding, workforce and digital infrastructure. 'Failure to act risks further undermining patient care and destabilising a community pharmacy sector that millions depend upon.' The APPG has laid out a number of recommendations, which includes a number of measures to better support patients. People impacted by shortages, particularly those with chronic conditions, struggle to find information on out of stock drugs, leading to 'frustration, dangerous delays in care, and unnecessary anxiety and harm', it said. It also welcomed work being carried out by the Department of Health and Social Care to potentially change pharmacist prescribing protocols to allow pharmacists to make dose and formulation changes during shortages. Elsewhere, the inquiry found more than eight in 10 pharmacists face daily shortages, with many spending hours every day finding alternative treatment and communicating with distressed patients. One told the APPG they are 'constantly firefighting'. Reacting to the report, Henry Gregg, chief executive of the National Pharmacy Association (NPA), said: 'Pharmacy teams are under enormous pressure but are forced to spend hours hunting down stock for distressed and frustrated patients. 'It is particularly frustrating for pharmacists to be unable to meet a clear need when they have a perfectly safe and effective solution in their pharmacy already. 'MPs are right that it is madness to send someone back to their GP to get a prescription changed, and it risks a patient either delaying taking vital medication or forgoing it altogether, which poses a clear risk to patient safety. 'As the APPG says, the Government must allow pharmacists – who are highly trained health care practitioners – to use their professional judgment to supply an appropriate alternative medication when the prescribed version is unavailable.' A Department of Health and Social Care spokesperson said: 'This government inherited ongoing global supply problems, but we have robust measures in place to mitigate disruption for patients. 'We are working to build the resilience of medicine supply chains and prevent future disruption as we get the NHS back on its feet. 'We have recently agreed an extra £617 million of funding over two years with Community Pharmacy England to support the sector and provide patients with more services closer to home as part of our 10 Year Health Plan.'
Powys County Times
29 minutes ago
- Powys County Times
‘Groundbreaking' drug could slow down progression of type 1 diabetes
A 'groundbreaking' drug to slow down the development of type 1 diabetes is being tried by a handful of patients in the UK. Teplizumab, which is already approved in the US, trains the immune system to stop attacking pancreatic cells, delaying the need for insulin by an average of three years. With type 1 diabetes, the immune system attacks insulin-producing cells in the pancreas, meaning blood sugar levels are no longer regulated by the body. If blood sugar is too high or low, it can cause serious health problems and even death. People with type 1 therefore need daily insulin. Dentist and mother-of-two, Hannah Robinson, from Devon, is the first adult in the UK to try the drug in the hope it can delay the condition. She is having treatment at the Royal Devon University Healthcare NHS Foundation Trust after discovering during pregnancy she was in the early stages of developing type 1. A handful of people are being given the medicine on a case-by-case basis while it is reviewed for wider use on the NHS. The 36-year-old said: 'For me, this new drug offers more freedom and the chance to focus on my health before I have to start thinking differently and managing life as somebody needing daily insulin. 'This isn't just about what I eat or monitoring my glucose, it is also about having more control and not feeling defined by my condition. 'This treatment could potentially pave the way for a future cure for type 1 diabetes, which is incredible. I feel very lucky to be part of this.' The new drug teplizumab must be given at the earliest stage of the disease to be effective. Dr Nick Thomas, diabetes consultant and academic clinical lecturer at the University of Exeter, said: 'This new treatment represents a really exciting shift in how we manage type 1 diabetes. 'For the first time ever, we will be able to provide targeted treatment early enough in the process to alter the underlying immune process, aiming to slow down how quickly people need insulin. 'Approximately half of all type 1 diabetes cases develop in adulthood, and Hannah will be the first adult in the UK to receive this treatment. 'My hope is that in the future, we may be able to stop people with early type 1 diabetes from needing insulin at all.' Experts at the Royal Devon and the University of Exeter are using genetics and other testing to spot people at high risk of developing type 1 diabetes. The hope is more people could be offered the drug to delay type 1. Dr Lucy Chambers, head of research impact and communications at Diabetes UK, said: 'For people in the early stages of type 1 diabetes, teplizumab offers a groundbreaking opportunity to buy them precious extra years insulin-free. 'Right now, it's only available in research settings – and while the excitement is real, urgent work is still needed to ensure it reaches everyone who could benefit. 'That means securing a UK licence for teplizumab, establishing national screening programmes to identify people with early-stage type 1 diabetes before symptoms appear, and preparing the NHS to deliver this treatment at scale. 'Diabetes UK is proud to be at the forefront of these efforts – funding pioneering research and working closely with the NHS towards a future where immunotherapies become the first-line treatment for tackling the autoimmune attack at the root of type 1 diabetes.' Professor Richard Oram, consultant physician at the Royal Devon and professor at the University of Exeter, said: 'Excitingly, teplizumab is the first drug with the potential to delay type 1 diabetes, but needs to be given before clinical diagnosis due to high blood glucose. 'It is really important to find new and improved approaches for identifying individuals at elevated risk.'
Rhyl Journal
2 hours ago
- Rhyl Journal
‘Groundbreaking' drug could slow down progression of type 1 diabetes
Teplizumab, which is already approved in the US, trains the immune system to stop attacking pancreatic cells, delaying the need for insulin by an average of three years. With type 1 diabetes, the immune system attacks insulin-producing cells in the pancreas, meaning blood sugar levels are no longer regulated by the body. If blood sugar is too high or low, it can cause serious health problems and even death. People with type 1 therefore need daily insulin. Dentist and mother-of-two, Hannah Robinson, from Devon, is the first adult in the UK to try the drug in the hope it can delay the condition. She is having treatment at the Royal Devon University Healthcare NHS Foundation Trust after discovering during pregnancy she was in the early stages of developing type 1. A handful of people are being given the medicine on a case-by-case basis while it is reviewed for wider use on the NHS. The 36-year-old said: 'For me, this new drug offers more freedom and the chance to focus on my health before I have to start thinking differently and managing life as somebody needing daily insulin. 'This isn't just about what I eat or monitoring my glucose, it is also about having more control and not feeling defined by my condition. 'This treatment could potentially pave the way for a future cure for type 1 diabetes, which is incredible. I feel very lucky to be part of this.' The new drug teplizumab must be given at the earliest stage of the disease to be effective. Dr Nick Thomas, diabetes consultant and academic clinical lecturer at the University of Exeter, said: 'This new treatment represents a really exciting shift in how we manage type 1 diabetes. 'For the first time ever, we will be able to provide targeted treatment early enough in the process to alter the underlying immune process, aiming to slow down how quickly people need insulin. 'Approximately half of all type 1 diabetes cases develop in adulthood, and Hannah will be the first adult in the UK to receive this treatment. 'My hope is that in the future, we may be able to stop people with early type 1 diabetes from needing insulin at all.' Experts at the Royal Devon and the University of Exeter are using genetics and other testing to spot people at high risk of developing type 1 diabetes. The hope is more people could be offered the drug to delay type 1. Dr Lucy Chambers, head of research impact and communications at Diabetes UK, said: 'For people in the early stages of type 1 diabetes, teplizumab offers a groundbreaking opportunity to buy them precious extra years insulin-free. 'Right now, it's only available in research settings – and while the excitement is real, urgent work is still needed to ensure it reaches everyone who could benefit. 'That means securing a UK licence for teplizumab, establishing national screening programmes to identify people with early-stage type 1 diabetes before symptoms appear, and preparing the NHS to deliver this treatment at scale. 'Diabetes UK is proud to be at the forefront of these efforts – funding pioneering research and working closely with the NHS towards a future where immunotherapies become the first-line treatment for tackling the autoimmune attack at the root of type 1 diabetes.' Professor Richard Oram, consultant physician at the Royal Devon and professor at the University of Exeter, said: 'Excitingly, teplizumab is the first drug with the potential to delay type 1 diabetes, but needs to be given before clinical diagnosis due to high blood glucose. 'It is really important to find new and improved approaches for identifying individuals at elevated risk.'
